G-CON Manufacturing Launches Transmissible Disease Containment POD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

G-CON Manufacturing Launches Transmissible Disease Containment POD


G-CON Manufacturing launched a transmissible disease containment (TDC) POD, the latest of its modular, autonomous cleanroom production structures. The TDC POD differs from the typical G-CON Manufacturing POD in width (8.5 feet), such that it is easily transported by tractor-trailer or its own axle system. The TDC PODs also have double bag-in/bag-out HEPA filters and will be equipped with their own generator units. All POD structures are readily deployable containment and cleanroom systems that include their own air handling systems and cleanable epoxy internal surfaces. All PODs can be cleaned with a number of methods, including vaporized hydrogen peroxide (VHP) or chlorine dioxide. Prefabricated PODs are typically built in 18 weeks. Integrated air bearings make additional support equipment unnecessary upon delivery.

"All our current POD systems already serve as either cleanroom environments and/or biosafety-level (BSL) containment systems," explained Maik Jornitz, president of G-CON Manufacturing, in a press release. "However, in light of recent events, we realized the need for even faster deployment and even better containment with redundancy functions in a transmissible disease application. The available alternatives are simply not robust enough, lack scaling capabilities, and cannot be properly sanitized for repeated uses. Each POD can hold a number of patients and equipment in a larger area, are easily deployable due to their robust aluminum structure, and represent the optimal containment due to redundant air filters. Moreover, available integrated VHP or other methodologies make cleaning as simple as pressing a button."

Source: G-CON Manufacturing

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here